In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at controlling the disease's progression. The study, published ...
Apr 5, 2018
0
873
Cancer therapies that target a specific protein have improved outcomes for patients. However, many patients eventually develop resistance to these targeted therapies and their cancer comes back. It is believed that differences ...
Apr 3, 2018
0
20
A single molecule of water is the reason certain mutations are more responsive to a 'targeted' cancer therapy, according to molecular-scale simulations carried out at the A*STAR Bioinformatics Institute.
Jan 16, 2018
0
3
A new study reveals that, among patients of advanced age with stage III lung cancer, African Americans and individuals who live in lower income areas are more likely to not receive any treatment. Published early online in ...
Jan 8, 2018
0
3
Johns Hopkins Kimmel Cancer Center researchers and colleagues have identified a novel drug combination therapy that could prime nonsmall cell lung cancers to respond better to immunotherapy. These so-called epigenetic therapy ...
Nov 30, 2017
0
205
A study led by Mayo Clinic researchers has found that proton beam therapy, in combination with chemotherapy, prior to surgery, may be a better option than a combination using traditional radiation therapy techniques with ...
Oct 25, 2017
0
0
In a feasibility trial of people with advanced lung cancer receiving radiation therapy, and their caregivers, yoga was beneficial to both parties. These findings will be presented at the upcoming 2017 Palliative and Supportive ...
Oct 24, 2017
0
0
Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, ...
Sep 25, 2017
0
0
Mesothelioma is a rare and aggressive tumor that, in many cases, results from exposure to asbestos. But over the last several decades, other causes of the disease have emerged, including treatment with high-intensity therapeutic ...
Sep 14, 2017
0
7
Durvalumab improves progression-free survival in patients with locally advanced, unresectable stage II lung cancer, according to late-breaking results from the phase III PACIFIC trial presented today at the ESMO 2017 Congress ...
Sep 11, 2017
0
12
